Montefiore Einstein Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Montefiore Einstein Comprehensive Cancer Center


Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions

December 11, 2023

Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.

Montefiore Einstein Comprehensive Cancer Center Awarded Comprehensive Designation from the National Cancer Institute

September 20, 2023

The newly renamed Montefiore Einstein Comprehensive Cancer Center has been awarded comprehensive designation by the National Cancer Institute of the National Institutes of Health, the ultimate standard achieved by only 55 other NCI cancer centers in the U.S.

Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice

September 20, 2023

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Racial Disparity Revealed in Prometastatic TME in Women With Residual Breast Cancer After Neoadjuvant Chemo

December 06, 2022

Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.

BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early

December 01, 2022

Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.